Skip to content
Pharma Observatory a Scientist.com platform

Condition (MeSH)

Anemia, Hemolytic

ClinicalTrials.gov lists 1,885 trials for Anemia, Hemolytic or a narrower condition beneath it. National Heart, Lung, and Blood Institute (NHLBI) has the most among industry and government lead sponsors, with 71.

MeSH D000743 Hemic and Lymphatic Diseases C15
Email me this page as a PDF

Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Phase 1 Phase 1 207 Phase 1/2 Phase 1/2 104 Phase 2 Phase 2 363 Phase 2/3 Phase 2/3 39 Phase 3 Phase 3 189 Phase 4 Phase 4 87 Not applicable Not applicable 365 Observational Observational 519 Phase 1 Phase 1 207 Phase 1/2 Phase 1/2 104 Phase 2 Phase 2 363 Phase 2/3 Phase 2/3 39 Phase 3 Phase 3 189 Phase 4 Phase 4 87 Not applicable Not applicable 365 Observational Observational 519

Trials per phase

1 more section with rows

55 of the 1,885 trials are tagged with Anemia, Hemolytic itself; the rest are tagged with a narrower condition beneath it.

Get the Anemia, Hemolytic report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

When did Anemia, Hemolytic trials start? (36)

Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year. 6 trials are registered to start in 2027 or later, and not listed here.

Trials over time, by phase

  • Phase 1
  • Phase 1/2
  • Phase 2
  • Phase 2/3
  • Phase 3
  • Phase 4
  • Not applicable
  • Observational
  • Other (Expanded access)

Top of scale: 126

1990: 1 trials (Observational 1) 1992: 2 trials (Phase 3 1, Phase 2 1) 1993: 2 trials (Observational 2) 1994: 3 trials (Phase 3 1, Phase 2 2) 1995: 3 trials (Observational 1, Not applicable 2) 1996: 1 trials (Phase 2 1) 1997: 6 trials (Not applicable 1, Phase 3 3, Phase 2 1, Phase 1 1) 1998: 3 trials (Observational 1, Phase 2 1, Phase 1 1) 1999: 10 trials (Not applicable 1, Phase 4 1, Phase 2 6, Phase 1/2 2) 2000: 12 trials (Observational 1, Not applicable 2, Phase 4 1, Phase 3 3, Phase 2 4, Phase 1 1) 2001: 14 trials (Observational 3, Not applicable 1, Phase 4 1, Phase 2 7, Phase 1 2) 2002: 12 trials (Observational 3, Not applicable 2, Phase 4 1, Phase 3 3, Phase 2/3 1, Phase 2 2) 2003: 16 trials (Observational 1, Not applicable 2, Phase 4 1, Phase 3 2, Phase 2/3 1, Phase 2 6, Phase 1/2 1, Phase 1 2) 2004: 32 trials (Observational 7, Not applicable 1, Phase 4 3, Phase 3 7, Phase 2 10, Phase 1/2 1, Phase 1 3) 2005: 36 trials (Observational 9, Not applicable 4, Phase 4 3, Phase 3 7, Phase 2 8, Phase 1/2 2, Phase 1 3) 2006: 40 trials (Other 1, Observational 13, Not applicable 2, Phase 4 1, Phase 3 10, Phase 2 7, Phase 1/2 3, Phase 1 3) 2007: 36 trials (Observational 13, Not applicable 4, Phase 4 2, Phase 3 2, Phase 2 12, Phase 1/2 2, Phase 1 1) 2008: 46 trials (Observational 17, Not applicable 6, Phase 4 1, Phase 3 1, Phase 2/3 3, Phase 2 10, Phase 1/2 5, Phase 1 3) 2009: 58 trials (Observational 20, Not applicable 8, Phase 4 3, Phase 3 1, Phase 2/3 3, Phase 2 14, Phase 1/2 7, Phase 1 2) 2010: 52 trials (Observational 18, Not applicable 10, Phase 4 1, Phase 3 4, Phase 2/3 1, Phase 2 11, Phase 1 7) 2011: 38 trials (Observational 12, Not applicable 3, Phase 4 3, Phase 3 3, Phase 2 9, Phase 1/2 4, Phase 1 4) 2012: 73 trials (Observational 25, Not applicable 14, Phase 4 1, Phase 3 4, Phase 2/3 4, Phase 2 15, Phase 1/2 4, Phase 1 6) 2013: 64 trials (Observational 19, Not applicable 13, Phase 4 4, Phase 3 3, Phase 2 14, Phase 1/2 5, Phase 1 6) 2014: 76 trials (Observational 18, Not applicable 16, Phase 4 4, Phase 3 2, Phase 2/3 4, Phase 2 18, Phase 1/2 7, Phase 1 7) 2015: 79 trials (Observational 14, Not applicable 19, Phase 4 9, Phase 3 6, Phase 2/3 1, Phase 2 10, Phase 1/2 5, Phase 1 15) 2016: 73 trials (Observational 19, Not applicable 19, Phase 4 4, Phase 3 9, Phase 2 13, Phase 1/2 4, Phase 1 5) 2017: 91 trials (Observational 22, Not applicable 13, Phase 4 5, Phase 3 9, Phase 2/3 1, Phase 2 27, Phase 1/2 5, Phase 1 9) 2018: 117 trials (Observational 30, Not applicable 27, Phase 4 5, Phase 3 15, Phase 2/3 5, Phase 2 20, Phase 1/2 5, Phase 1 10) 2019: 96 trials (Observational 27, Not applicable 17, Phase 4 4, Phase 3 15, Phase 2/3 3, Phase 2 19, Phase 1/2 3, Phase 1 8) 2020: 99 trials (Observational 27, Not applicable 23, Phase 4 5, Phase 3 10, Phase 2/3 3, Phase 2 13, Phase 1/2 5, Phase 1 13) 2021: 112 trials (Observational 40, Not applicable 21, Phase 4 5, Phase 3 15, Phase 2 18, Phase 1/2 3, Phase 1 10) 2022: 108 trials (Observational 30, Not applicable 26, Phase 4 3, Phase 3 14, Phase 2/3 3, Phase 2 16, Phase 1/2 6, Phase 1 10) 2023: 109 trials (Observational 34, Not applicable 23, Phase 4 5, Phase 3 6, Phase 2/3 3, Phase 2 18, Phase 1/2 5, Phase 1 15) 2024: 126 trials (Observational 39, Not applicable 33, Phase 4 5, Phase 3 9, Phase 2/3 1, Phase 2 13, Phase 1/2 6, Phase 1 20) 2025: 107 trials (Observational 29, Not applicable 24, Phase 4 2, Phase 3 12, Phase 2/3 1, Phase 2 13, Phase 1/2 4, Phase 1 22)

Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.

Trials started per year
Year Trials started
2026 (partial year) 105
2025 107
2024 126
2023 109
2022 108
2021 112
2020 99
2019 96
2018 117
2017 91

Showing 10 of 36 earlier years.

Start your 14-day trial Email me all 36 earlier years as a PDF

Forecast of the full-year count, planned starts included, not rows of this table: about 120 trials starting in 2026 and about 120 in 2027, the average of the 24 months through September, counted as registered and carried forward. The rows of this table count trials registered so far with a start date in the year, planned starts included; the forecast looks ahead to the count for the whole year, so it is not the same measure. In backtests on conditions of this size, forecasts made part-way through the year were typically off by about 13 percent and ran about 12 percent low against the count later registered; forecasts made before the year began were off by about 19 percent and ran about 17 percent low against the count later registered, and had about the same error as repeating last year's count. These figures rest on a few years of history (target years from 2018 to 2025, varying by figure), place each condition as it is mapped today rather than as it was then, and score against a count for the newest year that was still being revised. Only condition series were scored.

Prediction, not a registry value: median of 36 months from start to primary completion across 182 trials still running at the 2026-10-09 snapshot; registered median of 27 months across 1,155 trials with a primary completion typed Actual. Source: ClinicalTrials.gov / AACT (CTTI), public domain.

What phase are Anemia, Hemolytic trials in? (9)

Shown in this order: phase order.

Show the trials by phase as a table
Trials by phase
Phase Trials
Phase 1 207
Phase 1/2 104
Phase 2 363
Phase 2/3 39
Phase 3 189
Phase 4 87
Not applicable 365
Observational 519
Expanded access 12

How many Anemia, Hemolytic trials are recruiting? (13)

Shown in this order: the order a trial moves through, from not yet recruiting to unknown.

Trials by recruitment status
Status Trials
Not yet recruiting 99
Recruiting 253
Enrolling by invitation 15
Active, not recruiting 105
Available 6

Showing 5 of 13 statuses.

Start your 14-day trial Email me all 13 statuses as a PDF

Status as registered on ClinicalTrials.gov. Each trial is counted once.

Which lead sponsors run the most Anemia, Hemolytic trials? (4)

Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.

Lead sponsors
Sponsor Trials
National Heart, Lung, and Blood Institute (NHLBI) 71
Novartis Pharmaceuticals 63
Alexion Pharmaceuticals, Inc. 48
Pfizer 27

Which drugs are being tested for Anemia, Hemolytic? (6)

Shown in this order: most trials first. One row per drug, matched to a single molecule under all its names, ranked by number of trials.

Drugs tested
Drug Trials
Eculizumab 49
Cytoxan 36
Sirolimus 28
Voxelotor 21
Ravulizumab 20

Showing 5 of 6 drugs.

Start your 14-day trial Email me all 6 drugs as a PDF

Interventions as named in the registry (9)

Shown in this order: most trials first.

Interventions as named in the registry
Drug Trials
HU - Hydroxyurea 74
SQ Fludarabine 44
Alemtuzumab s.c. 32
Deferasirox FCT 32
Total Body Irradiation 24

Showing 5 of 9 interventions.

Start your 14-day trial Email me all 9 interventions as a PDF

These are the names sponsors entered on ClinicalTrials.gov that we have not matched to a single molecule. Some are drugs under a brand or code name; others are procedures, doses or arm labels.

Which serious adverse events do Anemia, Hemolytic trials report? (10)

Shown in this order: most subjects affected first. Subjects affected summed across trials, a cross-trial signal, not a rate.

Serious adverse events in this condition's trials
Adverse event Subjects affected Trials
Sickle cell anaemia with crisis 1,374 43
infections and infestations 346 1
Pyrexia 321 70
Pneumonia 311 71
Acute chest syndrome 299 33

Showing 5 of 10 adverse events.

Start your 14-day trial Email me all 10 adverse events as a PDF

Which publications cover Anemia, Hemolytic? (67)

Shown in this order: major-topic papers first, then newest, then most linked to trials.

Publications
Publication Journal Year Major topic
Oral Iptacopan Monotherapy in Paroxysmal Nocturnal Hemoglobinuria. The New England journal of medicine 2024 Yes
Sutimlimab provides clinically meaningful improvements in patient-reported outcomes in patients with cold agglutinin disease: Results from the randomised, placebo-controlled, Phase 3 CADENZA study. European journal of haematology 2023 Yes
Renal Thrombotic Microangiopathy: A Review. American journal of kidney diseases : the official journal of the National Kidney Foundation 2023 Yes
Successful treatment with daratumumab for post-HSCT refractory hemolytic anemia. Pediatric blood & cancer 2020 Yes
Inhibition of complement C1s improves severe hemolytic anemia in cold agglutinin disease: a first-in-human trial. Blood 2019 Yes

Showing 5 of 67 publications.

Start your 14-day trial Email me the first 50 publications as a PDF

Sub-conditions in MeSH (5)

MeSH descendants one level down with at least one trial, most trials first.

Not on this page

Not measured: delivery record.

Checked, with nothing recorded for this condition: prevalence and rare-disease identity.

Browse all condition evidence pages